Drug intelligence / Profile preview

GSK4528287

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK4528287 is an investigational drug developed by GSK for the treatment of inflammatory bowel diseases, specifically Crohn's disease and ulcerative colitis. It is currently being evaluated in a first-in-human Phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics, and target engagement in healthy participants. The precise mechanism of action has not been disclosed as of the latest updates. The drug represents a novel approach within the immunomodulator class for immune system and digestive system disorders[1][2][3][4][5].

Beyond the preview

Go deeper on GSK4528287.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK4528287.

Explore the full profile